钆特醇与钆贝葡胺在人脑组织中的钆滞留与清除比较
该研究通过尸体解剖脑、皮肤、骨组织,以电感耦合等离子体质谱分析,比较单用钆特醇(大环类)或钆贝葡胺(线型)后钆滞留与清除。结果显示钆贝葡胺的钆滞留中位数在大脑为钆特醇的3.0-6.5倍(P < .02)、骨为4.4倍(P = .002)、皮肤为2.9倍(P = .05);两种对比剂在白质和皮肤中均检出非零清除。
要点
- 线型钆贝葡胺在大脑和骨中的钆滞留中位数较大环类钆特醇高数倍,阅片报告时应关注对比剂类型。
- 两种对比剂滞留的钆在白质和皮肤均随时间呈现非零清除(白质和皮肤P值均小于0.05)。
- 脑内不同区域(苍白球、齿状核、白质)滞留差异明显,白质清除率相对较高。
核心结论
- 线型对比剂钆贝葡胺在大脑和骨中的钆滞留水平较大环类对比剂钆特醇高数倍,且两种对比剂滞留的钆在白质和皮肤中均检出非零清除。
研究设计与样本
- 尸体解剖研究,纳入2014年8月至2019年7月间暴露于单一类型对比剂(钆特醇或钆贝葡胺,单次或多次剂量)的病例,共28例钆特醇暴露者和9例钆贝葡胺暴露者(22名男性;年龄范围19-83岁),采用电感耦合等离子体质谱分析脑、皮肤、骨组织钆水平,用线性回归比较滞留并估算清除率。
诊断标准与关键数值
- 钆贝葡胺组较钆特醇组的钆滞留中位数:脑为3.0-6.5倍(P < .02),骨为4.4倍(P = .002),皮肤为2.9倍(P = .05)。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Linear gadolinium-based contrast agents (GBCAs) are known to be retained at higher levels of gadolinium than macro-cyclic GBCAs. However, very little is known regarding their relative elimination rates and retained fraction of injected gadolinium. Purpose To quantify and compare gadolinium retention and elimination rates in human brain tissue, skin, and bone obtained from cadavers exposed to single-agent administration of either gadoteridol (macrocyclic GBCA) or gadobenate dimeglumine (linear GBCA). Materials and Methods Autopsy cases from August 2014 to July 2019 of patients exposed to a single type of GBCA, either gadoteridol or gadobenate dimeglumine, either single or multiple doses, were included. Gadolinium levels in the brain, skin, and bone were analyzed with inductively coupled plasma mass spectrometry. Linear regression was used to compare gadolinium retention between agents and estimate elimination rates of the retained gadolinium using the time between last injection and death. Results Twenty-eight cadavers with gadoteridol exposure and nine with gadobenate dimeglumine exposure were identified (22 men; age range, 19-83 years). The median gadolinium retention of gadobenate dimeglumine was 3.0-6.5 times higher than that of gadoteridol in the brain (P < .02), 4.4 times higher in bone (P = .002), and 2.9 times higher in skin (P = .05). Gadolinium retention in the globus pallidus (GP), dentate nucleus (DN), white matter (WM), bone, and skin decreased with time elapsed from last administration to death in both the gadobenate dimeglumine (GP: -3% per twofold increase in time, P = .69; DN: -2%, P = .83; WM: -20%, P = .01; bone: -22%, P = .07; skin: -47%, P < .001) and gadoteridol (GP: -17%, P = .11; DN: -16%, P = .15; WM: -30%, P < .001; bone: -11%, P = .16; skin: -24%, P = .01) groups (P values for elimination are compared with a null hypothesis of no elimination). Conclusion The linear agent gadobenate dimeglumine retains several-fold higher levels of gadolinium in the brain and bone compared with the macrocyclic agent gadoteridol. Nonzero elimination of retained gadolinium was detected in the white matter and skin for both agents. © RSNA, 2021 Online supplemental material is available for this article. See also the editorial by Tweedle in this issue.
引用
- Kobayashi M, Levendovszky SR, Hippe DS, et al. Comparison of Human Tissue Gadolinium Retention and Elimination between Gadoteridol and Gadobenate. Radiology. 2021. PMID: 34128720. doi:10.1148/radiol.2021204320
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。